Bianco Andrea, Valente Tullio, De Rimini Maria Luisa, Sica Giacomo, Fiorelli Alfonso
Department of Cardio-Thoracic and Respiratory Sciences, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
Department of Radiology, A.O.R.N Dei Colli, Hospital Monaldi, Naples, Italy.
J Thorac Dis. 2018 Jan;10(Suppl 2):S253-S261. doi: 10.21037/jtd.2017.10.09.
Malignant pleural mesothelioma (MPM) is a tumour which, despite progress in diagnostic procedures and biomolecular research, has poor prognosis. Symptoms reflect extension of disease and include shortness of breath and chest pain. Unexplained pleural effusion and pleural pain in patients exposed to asbestos should raise the suspicion of MPM. MPM diagnosis requires imaging procedures X-ray and computed tomography (CT) scans; magnetic resonance imaging (MRI) better defines the extension of the tumor while PET scanning provides additional information on metabolic activity, metastases, and response to treatment. Thoracoscopic biopsy remains the most appropriate procedure for definitive diagnosis of mesothelioma. Multimodality treatment including surgery, chemotherapy and radiotherapy has been associated with a better survival in selected patients. Clinical translational research including new approaches targeting immune-checkpoints is opening new horizons which may lead to personalised treatments.
恶性胸膜间皮瘤(MPM)是一种肿瘤,尽管在诊断程序和生物分子研究方面取得了进展,但其预后仍然很差。症状反映了疾病的进展,包括呼吸急促和胸痛。接触石棉的患者出现不明原因的胸腔积液和胸痛应怀疑患有MPM。MPM的诊断需要进行影像学检查,如X射线和计算机断层扫描(CT);磁共振成像(MRI)能更好地确定肿瘤的范围,而正电子发射断层扫描(PET)则能提供有关代谢活性、转移情况和治疗反应的额外信息。胸腔镜活检仍然是确诊间皮瘤最合适的方法。包括手术、化疗和放疗在内的多模式治疗已使部分患者的生存率得到提高。包括针对免疫检查点的新方法在内的临床转化研究正在开辟新的前景,可能会带来个性化治疗。